Supplies of Johnson & Johnson’s Doxil cancer drug will be cut down in coming months as the company transitions to a new manufacturer.
In a letter recently posted on its website, J&J told doctors to expect a limited supply because the contract manufacturing organisation (CMO) currently producing the drug was moving out of the manufacturing biz.
Its current ‘speciality manufacturer’ is battling to increase production of the drugs over the next six weeks, however J&J has warned the amount will not be sufficient for all patients on the waiting lists.
The news comes after the New Jersey-based firm told doctors not to begin treating patients with Doxil in July.
At the time Doxil boasted annual sales figures of $500m (€367m).
The company is now working on finding a new CMO to produce the injectable.